Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).

Sophie Postel-Vinay,Vincent K Lam,Willeke Ros,Todd M Bauer,Aaron R Hansen,Daniel C Cho,F Stephen Hodi,Jan H M Schellens,Jennifer K Litton,Sandrine Aspeslagh,Karen A Autio,Frans L Opdam,Meredith McKean,Neeta Somaiah,Stephane Champiat,Mehmet Altan,Anna Spreafico,Osama Rahma,Elaine M Paul,Christoph M Ahlers,Helen Zhou,Herbert Struemper,Shelby A Gorman,Maura Watmuff,Kaitlin M Yablonski,Niranjan Yanamandra,Michael J Chisamore,Emmett V Schmidt,Axel Hoos,Aurelien Marabelle,Jeffrey S Weber,John V Heymach

Journal for immunotherapy of cancer（2023）

Cited 6|Views47
No score
Abstract
NCT02528357.
More
Translated text
Key words
antibodies, neoplasm,biomarkers, tumor,clinical trials as topic,costimulatory and inhibitory T-cell receptors,immunotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined